Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Abstract 2063 Poster Board II-40 Introduction: Adults with primary refractory or relapsed acute myeloid leukemia (AML) have a poor prognosis with complete responses to salvage therapy from 13-15% and a median survival of 1.5-6 months[1, 2]. From 2006-2009, 79 patients with relapsed or refractory acute myeloid leukemia were given salvage chemotherapy with decitabine 20mg/m 2 daily for 10 days or decitabine 20mg/m 2 × 5 days with gemtuzumab ozogamicin (GO) 3mg/m2 on day 5 at Weill Cornell Medical Center. Methods: Medical records of 79 patients who received decitabine-based salvage therapy were reviewed from September 2006 through July 2009 at Weill Cornell Medical College. Survival was calculated by the Kaplan Meir method and differences in survival calculated by the log-rank test using STATA software. Results: Twenty-five patients received decitabine-based therapy as first salvage, 32 patients as second salvage, and 22 patients as third or greater salvage. Fifty-one patients were treated with decitabine/GO and 29 patients received decitabine alone. Median age of patients was 65.5 years with a range of 24 -89 years (first salvage 75 years, second salvage 62 years, and third or greater salvage 64 years). Median survival of all patients was 205 days, range 7-732 days. Overall 34% patients responded: 16% CR ( 1000 and Plts > 100,000) with median survival not yet reached; 5% CRp ( 1000 and plts 1. Sievers, E.L., et al., Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse . J Clin Oncol, 2001. 19 (13): p. 3244-54. 2. Giles, F., et al., Outcome of patients with acute myelogenous leukemia after second salvage therapy . Cancer, 2005. 104 (3): p. 547-54. Disclosures: Off Label Use: Phase I trial of decitabine in AML is off-label .